aminosalicylic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2050 65-49-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aminosalicylic acid resin complex
  • potassium aminosalicylate
  • p-aminosalicylic acid
  • aminosalicylic acid
  • 4-Aminosalicylic acid
  • 4-Carboxy-3-hydroxyaniline
  • apacil
  • calcium aminosalicylate
  • sodium aminosalicylate
  • para-aminosalicylic acid
  • aminosalicylate potassium
  • aminosalicylate sodium
  • teebacin
An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.
  • Molecular weight: 153.14
  • Formula: C7H7NO3
  • CLOGP: 1.06
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 83.55
  • ALOGS: -1.11
  • ROTB: 1

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
12 g O
14 g O
14 g P
15 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 142.85 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1306.01 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
March 8, 1950 FDA CONSOLIDATED MIDLAND

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 130.17 51.59 23 181 2601 2355280
Electrocardiogram QT prolonged 116.48 51.59 25 179 7789 2350092
Anaemia 83.67 51.59 26 178 34766 2323115
Neuropathy peripheral 75.84 51.59 19 185 11413 2346468

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 250.25 61.74 50 206 5495 1741030
Hepatotoxicity 201.03 61.74 38 218 3046 1743479
Tuberculosis 114.67 61.74 22 234 1844 1744681
Drug resistance 96.95 61.74 21 235 3209 1743316
Anaemia 80.17 61.74 29 227 29428 1717097
Intentional product use issue 66.61 61.74 15 241 2704 1743821

Pharmacologic Action:

SourceCodeDescription
ATC J04AA01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Aminosalicylic acid and derivatives
ATC J04AA02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Aminosalicylic acid and derivatives
ATC J04AA03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Aminosalicylic acid and derivatives
CHEBI has role CHEBI:33231 antitubercular agent
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000995 Antitubercular Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute tuberculosis indication 25629007
Pulmonary tuberculosis indication 154283005 DOID:2957
Crohn's disease off-label use 34000006
Ulcerative colitis off-label use 64766004 DOID:8577
Goiter contraindication 3716002 DOID:12176
Peptic ulcer contraindication 13200003 DOID:750
Hypokalemia contraindication 43339004
Crystalluria contraindication 46784006
Chronic heart failure contraindication 48447003
Acidosis contraindication 51387008
Duodenal ulcer disease contraindication 51868009 DOID:1724
Kidney disease contraindication 90708001 DOID:557
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Cobalamin deficiency contraindication 190634004
Disease of liver contraindication 235856003 DOID:409
Gastric ulcer contraindication 397825006 DOID:10808

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.71 acidic
pKa2 12.94 acidic
pKa3 2.33 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cyclooxygenase Enzyme INHIBITOR CHEMBL CHEMBL
Tyrosine-protein phosphatase non-receptor type 1 Enzyme Kd 2.92 CHEMBL
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase Kinase WOMBAT-PK

External reference:

IDSource
4018852 VUID
N0000180192 NUI
C0030125 UMLSCUI
D00162 KEGG_DRUG
5B2658E0N2 UNII
133-09-5 SECONDARY_CAS_RN
255666002 SNOMEDCT_US
417238004 SNOMEDCT_US
10002 MMSL
4176 MMSL
d04226 MMSL
4018852 VANDF
7833 RXNORM
002845 NDDF
4649 PUBCHEM_CID
CHEBI:27565 CHEBI
CHEMBL1169 ChEMBL_ID
DB00233 DRUGBANK_ID
CHEMBL1200584 ChEMBL_ID
CHEMBL1200966 ChEMBL_ID
D010131 MESH_DESCRIPTOR_UI
CHEMBL2096646 ChEMBL_ID
CHEMBL2105983 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Paser HUMAN PRESCRIPTION DRUG LABEL 1 49938-107 GRANULE, DELAYED RELEASE 4 g ORAL ANDA 12 sections